S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
NASDAQ:ANIK

Anika Therapeutics (ANIK) Stock Price, News & Analysis

$25.84
+0.41 (+1.61%)
(As of 04/19/2024 ET)
Today's Range
$25.46
$25.97
50-Day Range
$23.31
$26.42
52-Week Range
$16.54
$28.13
Volume
49,278 shs
Average Volume
67,248 shs
Market Capitalization
$383.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.50

Anika Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
14.2% Upside
$29.50 Price Target
Short Interest
Bearish
5.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.12
Upright™ Environmental Score
News Sentiment
0.44mentions of Anika Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
20.54%
From $1.12 to $1.35 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.28 out of 5 stars

Medical Sector

403rd out of 909 stocks

Surgical & Medical Instruments Industry

47th out of 97 stocks

ANIK stock logo

About Anika Therapeutics Stock (NASDAQ:ANIK)

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

ANIK Stock Price History

ANIK Stock News Headlines

Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
ADC Therapeutics Q4 Earnings Preview
Earnings Outlook For Anika Therapeutics
Anika Therapeutics Inc (AKP.BE)
Anika Therapeutics, Inc. (ANIK)
See More Headlines
Receive ANIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/13/2024
Today
4/21/2024
Next Earnings (Confirmed)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Current Symbol
NASDAQ:ANIK
CUSIP
03525510
Employees
357
Year Founded
1992

Price Target and Rating

Average Stock Price Target
$29.50
High Stock Price Target
$37.00
Low Stock Price Target
$22.00
Potential Upside/Downside
+14.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-82,670,000.00
Pretax Margin
-51.20%

Debt

Sales & Book Value

Annual Sales
$166.66 million
Cash Flow
$5.00 per share
Book Value
$14.50 per share

Miscellaneous

Free Float
13,981,000
Market Cap
$383.72 million
Optionable
Optionable
Beta
0.76

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Cheryl Renee Blanchard Ph.D. (Age 60)
    President, CEO & Director
    Comp: $1.31M
  • Mr. Michael L. LevitzMr. Michael L. Levitz (Age 50)
    Executive VP, CFO & Treasurer
    Comp: $710.6k
  • Mr. David Colleran J.D. (Age 52)
    Executive VP, General Counsel & Corporate Secretary
    Comp: $664.54k
  • Ms. Anne Nunes (Age 55)
    Senior VP & COO
  • Mr. Ian W. McLeod
    VP & Chief Accounting Officer
  • Mr. Mark Namaroff (Age 61)
    Executive Director of Investor Relations & Corporate Communications
  • Mr. James Chase
    Senior Vice President of International Sales & Marketing
  • Mr. Ben Joseph
    Vice President of Commercial & Corporate Development
  • Ms. Lisa Funiciello
    Vice President of Human Resources

ANIK Stock Analysis - Frequently Asked Questions

Should I buy or sell Anika Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ANIK shares.
View ANIK analyst ratings
or view top-rated stocks.

What is Anika Therapeutics' stock price target for 2024?

2 brokers have issued 12 month price objectives for Anika Therapeutics' shares. Their ANIK share price targets range from $22.00 to $37.00. On average, they anticipate the company's stock price to reach $29.50 in the next year. This suggests a possible upside of 14.2% from the stock's current price.
View analysts price targets for ANIK
or view top-rated stocks among Wall Street analysts.

How have ANIK shares performed in 2024?

Anika Therapeutics' stock was trading at $22.66 on January 1st, 2024. Since then, ANIK stock has increased by 14.0% and is now trading at $25.84.
View the best growth stocks for 2024 here
.

When is Anika Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our ANIK earnings forecast
.

How can I listen to Anika Therapeutics' earnings call?

Anika Therapeutics will be holding an earnings conference call on Wednesday, May 8th at 5:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics, Inc. (NASDAQ:ANIK) issued its earnings results on Wednesday, March, 13th. The biotechnology company reported $0.05 EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.20. The biotechnology company had revenue of $42.97 million for the quarter, compared to analyst estimates of $41.51 million. Anika Therapeutics had a negative trailing twelve-month return on equity of 2.10% and a negative net margin of 49.60%.

What ETF holds Anika Therapeutics' stock?

Invesco Nasdaq Future Gen 200 ETF holds 1,676 shares of ANIK stock, representing 0.54% of its portfolio.

What guidance has Anika Therapeutics issued on next quarter's earnings?

Anika Therapeutics issued an update on its FY 2024 earnings guidance on Wednesday, March, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $168.0 million-$173.0 million, compared to the consensus revenue estimate of $179.4 million.

What other stocks do shareholders of Anika Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND).

Who are Anika Therapeutics' major shareholders?

Anika Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.44%). Insiders that own company stock include Cheryl R Blanchard, David Colleran, Jeffery S Thompson, John B Henneman III, Michael L Levitz and Raymond J Land.
View institutional ownership trends
.

How do I buy shares of Anika Therapeutics?

Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ANIK) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners